{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:46:23Z","timestamp":1792683983285,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.rpth.2026.106868","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T15:13:44Z","timestamp":1784214824000},"page":"106868","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrating pharmacovigilance and machine learning: bleeding signal detection and risk prediction for oral anticoagulants in cancer patients"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3900-7723","authenticated-orcid":false,"given":"Meina","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2026.106868_bib1","doi-asserted-by":"crossref","first-page":"483","DOI":"10.6004\/jnccn.2024.0046","article-title":"Cancer-associated venous thromboembolic disease, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Streiff","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.rpth.2026.106868_bib2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/17474086.2017.1257935","article-title":"Controversies in the management of cancer-associated thrombosis","volume":"10","author":"Carrier","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.rpth.2026.106868_bib3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.5045\/br.2022.2022025","article-title":"Challenging issues in the management of cancer-associated venous thromboembolism","volume":"57","author":"Yhim","year":"2022","journal-title":"Blood Res"},{"key":"10.1016\/j.rpth.2026.106868_bib4","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106868_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2009.12.023","article-title":"Venous thromboembolism and prognosis in cancer","volume":"125","author":"Khorana","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.106868_bib6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.amjcard.2017.04.009","article-title":"Rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation and active cancer","volume":"120","author":"Laube","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.rpth.2026.106868_bib7","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/s11239-018-1790-3","article-title":"Thromboembolism and bleeding in patients with cancer and mechanical heart valves","volume":"47","author":"Plaja","year":"2019","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.rpth.2026.106868_bib8","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1253\/circj.CJ-19-0515","article-title":"Cancer-associated venous thromboembolism in the real world\u2014from the COMMAND VTE registry","volume":"83","author":"Sakamoto","year":"2019","journal-title":"Circ J"},{"issue":"Suppl 1","key":"10.1016\/j.rpth.2026.106868_bib9","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/S0049-3848(16)30104-9","article-title":"Clinical course of upper extremity deep vein thrombosis in patients with or without cancer: a systematic review","volume":"140","author":"Bleker","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.106868_bib10","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ajh.25059","article-title":"Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer","volume":"93","author":"Streiff","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.rpth.2026.106868_bib11","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.thromres.2023.12.016","article-title":"Cancer-associated venous thromboembolism in the direct oral anticoagulants era: insight from the COMMANDVTE registry-2","volume":"234","author":"Chatani","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.106868_bib12","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1365-2125.2006.02806.x","article-title":"Warfarin: almost 60 years old and still causing problems","volume":"62","author":"Pirmohamed","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.rpth.2026.106868_bib13","first-page":"426","article-title":"Anticoagulation: updated guidelines for outpatient management","volume":"100","author":"Wigle","year":"2019","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.rpth.2026.106868_bib14","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106868_bib15","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.rpth.2026.106868_bib16","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rpth.2026.106868_bib17","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106868_bib18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40780-016-0048-5","article-title":"Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis using the Japanese adverse drug event report database","volume":"2","author":"Abe","year":"2016","journal-title":"J Pharm Health Care Sci"},{"key":"10.1016\/j.rpth.2026.106868_bib19","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","article-title":"Illustration of the Weibull shape parameter signal detection tool using electronic healthcare record data","volume":"36","author":"Sauzet","year":"2013","journal-title":"Drug Saf"},{"key":"10.1016\/j.rpth.2026.106868_bib20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40780-015-0035-2","article-title":"Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events","volume":"1","author":"Nakamura","year":"2015","journal-title":"J Pharm Health Care Sci"},{"key":"10.1016\/j.rpth.2026.106868_bib21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/14740338.2023.2295397","article-title":"The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the food and drug administration Adverse Event Reporting System (FAERS)","volume":"23","author":"McIntyre","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.rpth.2026.106868_bib22","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1002\/bjs.10895","article-title":"LASSO regression","volume":"105","author":"Ranstam","year":"2018","journal-title":"J Br Surg"},{"key":"10.1016\/j.rpth.2026.106868_bib23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41580-021-00407-0","article-title":"A guide to machine learning for biologists","volume":"23","author":"Greener","year":"2022","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.rpth.2026.106868_bib24","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1182\/bloodadvances.2022007263","article-title":"Incidence and clinical impact of bleeding events in older patients with acute venous thromboembolism","volume":"7","author":"Ferrazzini","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.106868_bib25","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"10.1016\/j.rpth.2026.106868_bib26","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106868_bib27","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.chest.2021.09.037","article-title":"Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial","volume":"161","author":"Planquette","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.rpth.2026.106868_bib28","article-title":"Direct oral anticoagulants for venous thromboembolism in cancer patients: a systematic review and network meta-analysis","volume":"30","author":"Wu","year":"2022","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.rpth.2026.106868_bib29","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/imj.15049","article-title":"Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and network meta-analysis","volume":"52","author":"Samaranayake","year":"2022","journal-title":"Intern Med J"},{"key":"10.1016\/j.rpth.2026.106868_bib30","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1056\/NEJMoa2510703","article-title":"Bleeding risk with apixaban vs. rivaroxaban in acute venous thromboembolism","volume":"394","author":"Castellucci","year":"2026","journal-title":"N Engl J Med"},{"issue":"7 Suppl","key":"10.1016\/j.rpth.2026.106868_bib31","first-page":"S24","article-title":"Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban","volume":"29","author":"Gong","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.rpth.2026.106868_bib32","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11239-013-1029-2","article-title":"A clinical and pharmacologic assessment of oncedaily versus twice-daily dosing for rivaroxaban","volume":"38","author":"Kreutz","year":"2014","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.rpth.2026.106868_bib33","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.chest.2016.07.013","article-title":"Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation","volume":"150","author":"Noseworthy","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.rpth.2026.106868_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0205989","article-title":"Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban","volume":"13","author":"Tepper","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.rpth.2026.106868_bib35","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rpth.2026.106868_bib36","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1080\/03007995.2021.1932448","article-title":"Effectiveness and safety of apixaban, LMWH, and warfarin among high-risk subgroups of VTE patients with active cancer","volume":"37","author":"Cohen","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.rpth.2026.106868_bib37","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/cncr.33470","article-title":"Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: a nationwide cohort study","volume":"127","author":"Pastori","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.rpth.2026.106868_bib38","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s11739-022-03156-w","article-title":"Bleeding and thrombotic events in atrial fibrillation patients with cancer: a systematic review and meta-analysis","volume":"18","author":"Pastori","year":"2023","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.rpth.2026.106868_bib39","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1002\/ijc.33179","article-title":"Cancer-specific ischemic complications in elderly patients with atrial fibrillation: data from the prospective ATHERO-AF study","volume":"147","author":"Pastori","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.rpth.2026.106868_bib40","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2146\/ajhp170529","article-title":"Signal detection for bleeding associated with the use of direct oral anticoagulants","volume":"75","author":"Nathan","year":"2018","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.rpth.2026.106868_bib41","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.7326\/M21-1474","article-title":"Rivaroxaban is associated with higher rates of gastrointestinal bleeding than other direct oral anticoagulants: a nationwide propensity score-weighted study","volume":"174","author":"Ingason","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rpth.2026.106868_bib42","doi-asserted-by":"crossref","first-page":"51","DOI":"10.7326\/M18-1376","article-title":"PROBAST: a tool to assess the risk of bias and applicability of prediction model studies","volume":"170","author":"Wolff","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rpth.2026.106868_bib43","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1111\/jth.15759","article-title":"Standardization of risk prediction model reporting in cancer-associated thrombosis: communication from the ISTH SSC subcommittee on hemostasis and malignancy","volume":"20","author":"Sanfilippo","year":"2022","journal-title":"J Thromb Haemost"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926035260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926035260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:24:54Z","timestamp":1792682694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926035260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2475037926035260"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106868","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrating pharmacovigilance and machine learning: bleeding signal detection and risk prediction for oral anticoagulants in cancer patients","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106868","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"106868"}}